. Overview We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients. Acute Care Product Portfolio ZYNRELEF ZYNRELEF is a dual-acting...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073515 | EDGAR | 69K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028374 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0000950170-24-029951 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010603 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007618 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-007841 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001564590-20-007973 | EDGAR | — |
| 2019-02-22 | 2018-12-31 | 0001193125-19-047780 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001193125-18-060951 | EDGAR | — |
| 2017-02-23 | 2016-12-31 | 0001193125-17-054088 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-263618 | EDGAR | 26K words |
| 2025-08-08 | 2025-06-30 | 0000950170-25-105475 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063971 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124698 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091764 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053964 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063714 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042431 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021237 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001564590-22-037047 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028599 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001564590-22-018877 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0001193125-26-142947 | EDGAR | 9K words |
| 2026-02-26 | 0001193125-26-073502 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008631 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263617 | EDGAR | — |
| 2025-10-29 | 0001193125-25-256300 | EDGAR | — |
| 2025-10-15 | 0001193125-25-240253 | EDGAR | — |
| 2025-08-28 | 0000950170-25-112048 | EDGAR | — |
| 2025-08-15 | 0000950170-25-109234 | EDGAR | — |
| 2025-08-12 | 0000950170-25-107416 | EDGAR | — |
| 2025-08-12 | 0000950170-25-107404 | EDGAR | — |
360 total filings indexed. 328 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000818033 |
| Ticker | HRTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.herontx.com |
| Listed | 1987-08-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report